top of page

Conclusions & Recommendations

20.2.2 - ITI Supply Chain Team

Conclusion/Recommendation:

TEC recommends that the ITI Supply Chain team finalize and share their SOPs and other supply chain tools with other NTD programs.

Action:

This is being achieved through the NTD Supply Chain Forum.

TEC 20

2019

supply chain

20.2.3 - ITI Supply Chain Team

Conclusion/Recommendation:

TEC recommends to ITI management to invite supply chain and management representatives from the other NTD pharmaceutical donors to future Summer TEC meetings.

Action:

ITI Management will continue to invite representatives from the other pharmaceutical companies, and would welcome TEC members’ suggestions of specific key invitees. Previous invitees have been unable to attend. TEC 22’s online format facilitated participation from a broader range of interested parties.

TEC 20

2019

supply chain, recommendations for ITI management, TEC meeting management

20.3.1 - WHO participation as Observers at TEC

Conclusion/Recommendation:

TEC acknowledged the presence of the World Health Organization representatives from Headquarters, PAHO, and ESPEN/AFRO and recommend that an open invitation be extended to them (and other WHO Regional Offices, as appropriate) as Observers at future TEC meetings.

Action:

This is noted and ITI Management will continue to invite WHO representatives from the regional offices, as determined by agenda topics and meeting location.

TEC 20

2019

TEC meeting management

20.4.1 - Engagement with DFID and Crown Agents for Ascend Funding

Conclusion/Recommendation:

TEC notes that for 2020, 14.5 million treatments in 86 districts were approved contingent on confirmation of funding where the presumed funding source is DFID/Ascend-Crown Agents, and where implementing partners are not yet identified. Given that Crown Agents is a new entity in the implementation of NTD programs, TEC recommends that ITI work closely with DFID-Ascend and Crown Agents to identify funding needs, support the inception phase, and identify where future assistance may be required.

Action:

ITI Management have been in contact with Crown Agents to provide the 2019 and 2020 funding gaps list, in areas previously supported by DFID funding. A Crown Agents representative was again invited to participate in the TEC 21 meeting; unfortunately, they were unable to send anyone. ITI Management will continue to engage with them. ITI continued to welcome engagement with Crown Agents, and Crown were invited as Observers at TEC 22.

TEC 20

2019

funding, recommendations for ITI management

20.5.1 - Ethiopia

Conclusion/Recommendation:

TEC recommends to ITI to include a clause in the MOU with Ethiopia to require Zithromax® inventory reporting prior to each shipment, upon request.

Action:

A clause was included in the 2020 MOU.

TEC 20

2019

Africa - East

Ethiopia

supply chain, recommendations for ITI management

20.6.1 - Ethiopia: Gambella

Conclusion/Recommendation:

Due to high population movement, TEC recommends that ITI request that the Ethiopian FMOH and Gambella RHB provide new population figures for each refugee camp.

Action:

This will be done for the 2021 Zithromax® Application. For TEC 22, the population of refugee camps was updated through Ethiopia’s Administration for Refugee and Returnee Affairs (ARRA) and reflected in the 2021 Zithromax® Application.

TEC 20

2019

Africa - East

Ethiopia

special populations, Zithromax® donation criteria

20.7.1 - Kenya

Conclusion/Recommendation:

TEC congratulates the Kenya MOH for their new NTD strategy and strong political engagement in the fight against NTDs. The trachoma elimination program is encouraged to ensure excellent implementation of the SAFE strategy, including high coverage, and on-time MDAs. TEC notes that reaching the TF threshold by 2022 is expected based on effective implementation and may not require anything that differs from current strategy.

Action:

This message was conveyed to the Kenya National Trachoma Program. The ITI Director and Regional Director for Africa are included on the Advisory Body for Kenya’s new NTD strategy.
The Kenya trachoma program moved from the Prevention of Blindness in the Non-Communicable Disease department to the NTD program in the Infectious Disease department.

TEC 20

2019

Africa - East

Kenya

20.7.2 - Kenya

Conclusion/Recommendation:

If the Kenyan program would like to propose an evidence-based strategy to accelerate and sustain elimination of trachoma as a public health problem, particularly in areas or populations of concern (e.g., due to migration), TEC would consider such a proposal at the next meeting in November 2019.

Action:

This message was conveyed to the Kenya National Trachoma Program; no proposals were received for TEC 21.
As of TEC 22, there was no new update from Kenya. ITI management reconsidered allocation of resources to operational research and did not actively pursue this.

TEC 20

2019

Africa - East

Kenya

alternative treatment strategies, special populations, TEC meeting management

20.8.1 - South Sudan: Juba ‘Protection of Civilians’ Camp

Conclusion/Recommendation:

TEC approves the request for a second round of MDA in the Juba POC camp, although TF1-9 prevalence for the camp has not been measured. A population-based prevalence survey will be needed after three rounds (or sooner, if feasible) to establish future eligibility for MDA.

Action:

This message was conveyed to the South Sudan National Trachoma Program.
As of TEC 22, the second round of MDA was planned.

TEC 20

2019

Africa - East

South Sudan

Zithromax® donation criteria, special populations

20.9.1 - Zithromax® for Refugees: Decision Making Algorithm

Conclusion/Recommendation:

TEC recommends that ITI update the refugee algorithm’s level 3 to say “Does host district have TF1-9 ≥5%?”

Action:

The refugee algorithm has been updated and the new version is included in the TEC 21 documents.

TEC 20

2019

special populations, Zithromax® donation criteria

International Trachoma Initiative

330 West Ponce de Leon Avenue

Decatur, GA 30030 

Phone:

+1 800 765 7173
+1 404 371 0466
Fax:

+1 404 371 1087

  • Instagram
  • Facebook
  • Twitter
  • YouTube
bottom of page